This Article  • Full text  • PDF  • Author in the Room Teleconference  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (72)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Systematic Review

Charles L. Campbell, MD; Susan Smyth, MD, PhD; Gilles Montalescot, MD, PhD; Steven R. Steinhubl, MD

JAMA. 2007;297(18):2018-2024.

Context  More than 50 million US adults take aspirin regularly for long-term prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding the most appropriate long-term daily dose.

Objective  To review the mechanism of action of aspirin and the clinical literature for relationships among aspirin dosage, efficacy, and safety.

Evidence Acquisition  A systematic review of the English-language literature was undertaken using MEDLINE and EMBASE (searched through February 2007) and the search term aspirin or acetylsalicylic acid and dose. The search was limited to clinical trials and was extended by a review of bibliographies of pertinent reports of original data and review articles. Published prospective studies using different aspirin dosages in the setting of cardiovascular disease were included.

Evidence Synthesis  Although pharmacodynamic data demonstrate that long-term aspirin dosages as low as 30 mg/d are adequate to fully inhibit platelet thromboxane production, dosages as high as 1300 mg/d are approved for use. In the United States, 81 mg/d of aspirin is prescribed most commonly (60%), followed by 325 mg/d (35%). The available evidence, predominantly from secondary-prevention observational studies, supports that dosages greater than 75 to 81 mg/d do not enhance efficacy, whereas larger dosages are associated with an increased incidence of bleeding events, primarily related to gastrointestinal tract toxicity.

Conclusions  Currently available clinical data do not support the routine, long-term use of aspirin dosages greater than 75 to 81 mg/d in the setting of cardiovascular disease prevention. Higher dosages, which may be commonly prescribed, do not better prevent events but are associated with increased risks of gastrointestinal bleeding.

Author Affiliations: Gill Heart Institute, University of Kentucky, Lexington (Drs Campbell, Smyth, and Steinhubl); and Institut de Cardiologie—Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France (Dr Montalescot).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Aspirin Dose and Cardiovascular Disease Prevention
Andrew Clegg
JAMA. 2007;298(6):625.
EXTRACT | FULL TEXT  

Aspirin Dose and Cardiovascular Disease Prevention
George Kwok Chu Wong
JAMA. 2007;298(6):625.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research.
Redberg et al.
J Am Coll Cardiol 2009;54:1364-1405.
FULL TEXT  

ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research
WRITING COMMITTEE MEMBERS et al.
Circulation 2009;120:1296-1336.
FULL TEXT  

Review: Platelet Function Testing and Implications for Clinical Practice
Collet and Montalescot
J CARDIOVASC PHARMACOL THER 2009;14:157-169.
ABSTRACT  

Aspirin resistance testing not ready for "prime time"
Hjemdahl
Heart 2009;95:1220-1222.
FULL TEXT  

Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials
Berger et al.
JAMA 2009;301:1909-1919.
ABSTRACT | FULL TEXT  

Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study
Jolly et al.
Eur Heart J 2009;30:900-907.
ABSTRACT | FULL TEXT  

Aspirin following PCI: too much of a good thing?
Steinhubl and Berger
Eur Heart J 2009;30:882-884.
FULL TEXT  

Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding
Steinhubl et al.
ANN INTERN MED 2009;150:379-386.
ABSTRACT | FULL TEXT  

Commencing antiplatelet therapy in older people after an acute ischaemic stroke
Fletcher et al.
Age Ageing 2009;38:142-144.
FULL TEXT  

Aspirin Use, Dose, and Clinical Outcomes in Postmenopausal Women With Stable Cardiovascular Disease: The Women's Health Initiative Observational Study
Berger et al.
Circ Cardiovasc Qual Outcomes 2009;2:78-87.
ABSTRACT | FULL TEXT  

Use of Aspirin, Other Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen and Risk of Breast Cancer Among Premenopausal Women in the Nurses' Health Study II
Eliassen et al.
Arch Intern Med 2009;169:115-121.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2009
American Diabetes Association
Diabetes Care 2009;32:S13-S61.
FULL TEXT  

Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk
Eikelboom et al.
Circulation 2008;118:1705-1712.
ABSTRACT | FULL TEXT  

Review: Prevention of coronary heart disease in women
Rohit Seth Loomba and Arora
Ther Adv Cardiovasc Dis 2008;2:321-327.
ABSTRACT  

A Practical 'ABCDE' Approach to the Metabolic Syndrome
Blaha et al.
Mayo Clin Proc. 2008;83:932-943.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT | FULL TEXT  

The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Becker et al.
Chest 2008;133:776S-814S.
ABSTRACT | FULL TEXT  

The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance
Gasparyan et al.
J Am Coll Cardiol 2008;51:1829-1843.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review
O'Donnell et al.
Stroke 2008;39:1638-1646.
ABSTRACT | FULL TEXT  

Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging
Bulckaen et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1562-H1570.
ABSTRACT | FULL TEXT  

Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy
Berger et al.
Circulation 2008;117:192-199.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Wiviott et al.
NEJM 2007;357:2001-2015.
ABSTRACT | FULL TEXT  

Other articles noted
Evid. Based Med. 2007;12:159-160.
FULL TEXT  

Sophia
Roop and Wyatt
Emerg. Med. J. 2007;24:686-686.
FULL TEXT  

Aspirin Dose and Cardiovascular Disease Prevention
Clegg
JAMA 2007;298:625-625.
FULL TEXT  

Aspirin Dose and Cardiovascular Disease Prevention
Wong
JAMA 2007;298:625-625.
FULL TEXT  

How Much Daily Aspirin Is Best?
JWatch Emergency Med. 2007;2007:3-3.
FULL TEXT